U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H21N5O2S
Molecular Weight 323.4155
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ABROCITINIB

SMILES

CCCS(=O)(=O)N[C@@]1([H])C[C@]([H])(C1)N(C)c2c3cc[nH]c3ncn2

InChI

InChIKey=IUEWXNHSKRWHDY-PHIMTYICSA-N
InChI=1S/C14H21N5O2S/c1-3-6-22(20,21)18-10-7-11(8-10)19(2)14-12-4-5-15-13(12)16-9-17-14/h4-5,9-11,18H,3,6-8H2,1-2H3,(H,15,16,17)/t10-,11+

HIDE SMILES / InChI

Molecular Formula C14H21N5O2S
Molecular Weight 323.4155
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: The description was created based on several sources, including https://clinicaltrials.gov/ct2/show/NCT02201524 | https://www.google.com/patents/WO2014128591A1 | https://clinicaltrials.gov/ct2/show/NCT02780167

PF-04965842 is an orally administered selective Janus kinase 1 (JAK1) inhibitor. PF-04965842 is currently in clinical trials for the treatment of autoimmune diseases.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
29.0 nM [IC50]
803.0 nM [IC50]
1259.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3334 ng/mL
400 mg 1 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
PF-04965842 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
3712 ng/mL
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PF-04965842 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
18230 ng × h/mL
400 mg 1 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
PF-04965842 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
23740 ng × h/mL
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PF-04965842 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4.85 h
400 mg 1 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
PF-04965842 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
4.88 h
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PF-04965842 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
PubMed

PubMed

TitleDatePubMed
Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.
2017 Feb
Patents

Patents

Sample Use Guides

200 mg daily, 400 mg daily and 200 mg twice daily for 4 weeks
Route of Administration: Oral
Canine whole blood was collected in sodium heparin tubes from 29 beagle dogs and 23 mixed breed dogs. Whole blood (20 μL) was plated in 96-well plates (Costar 3598) with 180 μL of medium (RPMI 1640, Gibco #21870-076, with 1% heat inactivated fetal bovine serum, Gibco #10082-39, 292 μg/ml L-glutamine, Gibco #250030-081, 100 u/ml penicillin and 100μg streptomycin per ml, Gi bco #15 140- 122) containing vehicle control or test compound (0.001 to 10 μΜ), concanavalin A (ConA; 1 μg/ml, Sigma C5275), and canine inter-leukin-2 (IL-2 ; 50 ng/ml , R&D Systems 1815-CL/CF). Wells containing whole blood, medium with vehicle control and no ConA or I L-2 were used as background controls. Plates were incubated at 37° C for 48 hours. Tritiated thymidine, 0.4 μα/well (Perkin Elmer, Net027A-005 MC), was added for 20 additional hours. Plates were frozen and then thawed, washed and filtered using a Brandel MLR-96 cell harvester and pre-wet filter mats (Wallac 1205-401, Perkin Elmer). Filters were d ried at 60° C for one hour (Precision 16EG convection oven) and placed into filter sample bags (Wallac 1205-411, Perkin Elmer) with 10 mL of scintillant (Wallac 1205-440, Perkin Elmer). Sealed filters were counted on a LKB Wallac 1205 Betaplate liquid scintillation counter.
Substance Class Chemical
Created
by admin
on Sat Jun 26 10:51:45 UTC 2021
Edited
by admin
on Sat Jun 26 10:51:45 UTC 2021
Record UNII
73SM5SF3OR
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ABROCITINIB
INN  
Official Name English
PF-04965842
Code English
N-(CIS-3-(METHYL(7H-PYRROLO(2,3-D)PYRIMIDIN-4-YL)AMINO)CYCLOBUTYL)PROPANE-1-SULFONAMIDE
Systematic Name English
1-PROPANESULFONAMIDE, N-(CIS-3-(METHYL-7H-PYRROLO(2,3-D)PYRIMIDIN-4-YLAMINO)CYCLOBUTYL)-
Systematic Name English
ABROCITINIB [INN]
Common Name English
ABROCITINIB [WHO-DD]
Common Name English
N-((1S,3S)-3-(METHYL(7H-PYRROLO(2,3-D)PYRIMIDIN-4-YL)AMINO)CYCLOBUTYL)PROPANE-1-SULFONAMIDE
Systematic Name English
ABROCITINIB [USAN]
Common Name English
N-(3-(METHYL(7H-PYRROLO(2,3-D)PYRIMIDIN-4-YL)AMINO)CYCLOBUTYL)PROPANE-1-SULFONAMIDE, CIS-
Systematic Name English
Code System Code Type Description
ChEMBL
CHEMBL3544929
Created by admin on Sat Jun 26 10:51:45 UTC 2021 , Edited by admin on Sat Jun 26 10:51:45 UTC 2021
PRIMARY
PUBCHEM
78323835
Created by admin on Sat Jun 26 10:51:45 UTC 2021 , Edited by admin on Sat Jun 26 10:51:45 UTC 2021
PRIMARY
CAS
1622902-68-4
Created by admin on Sat Jun 26 10:51:45 UTC 2021 , Edited by admin on Sat Jun 26 10:51:45 UTC 2021
PRIMARY
NCI_THESAURUS
C166985
Created by admin on Sat Jun 26 10:51:45 UTC 2021 , Edited by admin on Sat Jun 26 10:51:45 UTC 2021
PRIMARY
FDA UNII
73SM5SF3OR
Created by admin on Sat Jun 26 10:51:45 UTC 2021 , Edited by admin on Sat Jun 26 10:51:45 UTC 2021
PRIMARY
DRUG BANK
DB14973
Created by admin on Sat Jun 26 10:51:45 UTC 2021 , Edited by admin on Sat Jun 26 10:51:45 UTC 2021
PRIMARY
INN
11012
Created by admin on Sat Jun 26 10:51:45 UTC 2021 , Edited by admin on Sat Jun 26 10:51:45 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY